Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gap junction protein beta-7 is a connexin family ion channel also known as Connexin-25, encoded by the GJB7 gene. Connexins are integral plasma membrane proteins that oligomerize into hexameric structures called connexons, which dock with connexons from adjacent cells to form gap junction channels[1][2][4]. These channels directly connect the cytoplasms of neighboring cells, enabling the rapid diffusion of ions, metabolites (e.g., glucose), and signaling molecules (e.g., cAMP, IP3) with a molecular weight of up to ~1 kDa[2][4][5][7]. GJB7 is less studied than other connexins and is not established as a direct therapeutic target[2][3][5]. It is present in various tissues and contributes to cellular signaling and metabolic cooperation, predominantly in the context of intercellular communication and tissue homeostasis[2][3][7]. There are no current drugs or therapies known to modulate its function directly, nor is it used as a biomarker or subject to reported clinical safety issues[1][2][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gap junction protein beta-7 (GJB7).